Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.

Publication Cover

“Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions.

Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical development.

This commentary discusses the unique challenges and merits of botanical vs single molecule cannabinoid drug development strategies, highlights how both can be impacted by legalization of cannabis via legislative processes, and also addresses regulatory and public health considerations that are important to consider as cannabinoid medicine advances as a discipline.”

https://www.ncbi.nlm.nih.gov/pubmed/30179534

https://www.tandfonline.com/doi/abs/10.1080/09540261.2018.1474730?journalCode=iirp20

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Leave a Reply

Your email address will not be published. Required fields are marked *